⭐⭐⭐⭐⭐ Amphotericin B Case Summary

Saturday, July 24, 2021 5:32:23 AM

Amphotericin B Case Summary



Article Google Scholar 7. JAMA Ophthalmol ; Amphotericin B Case Summary Mestranol; Norethindrone: Amphotericin B Case Summary Estrogen containing oral contraceptives can induce fluid Amphotericin B Case Summary and may increase blood pressure in some patients; monitor Amphotericin B Case Summary receiving concurrent therapy to confirm that the desired antihypertensive effect is being obtained. Iloperidone: Moderate Secondary to alpha-blockade, iloperidone can produce vasodilation that may result Amphotericin B Case Summary additive effects during Human Nature In Hawthornes Young Goodman Brown use with antihypertensive agents. Fungal infection and mesomycetozoea. Gallium Ga Amphotericin B Case Summary Dotatate: Major Amphotericin B Case Summary use Essay On Their Eyes Were Watching God Amphotericin B Case Summary diuretics with mannitol, if possible. Belladonna; Opium: Moderate Monitor for decreased diuretic efficacy Amphotericin B Case Summary Biodiversity Pros And Cons orthostatic hypotension when loop diuretics are Amphotericin B Case Summary with opium.

Amphotericin B - Mechanism, side effects, precautions and uses

CoQ10 use in combination with antihypertensive agents may lead to additional reductions in blood pressure in some individuals. Patients who choose to take CoQ10 concurrently with antihypertensive medications should receive periodic blood pressure monitoring. Patients should be advised to inform their prescriber of their use of CoQ Colchicine; Probenecid: Moderate Probenecid can interfere with the natriuresis and plasma renin activity increases caused by diuretics such as furosemide. Furosemide can in turn increase the levels of serum uric acid, antagonizing the effects of probenecid. Conivaptan: Moderate There is potential for additive hypotensive effects when conivaptan is coadministered with antihypertensive agents.

Cosyntropin: Moderate Use cosyntropin cautiously in patients receiving diuretics. Cosyntropin may accentuate the electrolyte loss associated with diuretic therapy. Cyclosporine: Moderate Coadministration of furosemide and cyclosporine increases the risk of gouty arthritis. This is a result of furosemide-induced hyperuricemia and the impairment of renal urate excretion by cyclosporine. Dapagliflozin: Moderate Loop diuretics can decrease the hypoglycemic effects of antidiabetic agents by producing an increase in blood glucose concentrations. Patients receiving dapagliflozin should be monitored for changes in blood glucose control if such diuretics are added or deleted.

Dapagliflozin; Metformin: Moderate Loop diuretics can decrease the hypoglycemic effects of antidiabetic agents by producing an increase in blood glucose concentrations. Dapagliflozin; Saxagliptin: Moderate Loop diuretics can decrease the hypoglycemic effects of antidiabetic agents by producing an increase in blood glucose concentrations. Because of this, a potential pharmacodynamic interaction exists between these drugs and all antidiabetic agents. Darifenacin: Minor Diuretics can increase urinary frequency, which may aggravate bladder symptoms. Dasabuvir; Ombitasvir; Paritaprevir; Ritonavir: Moderate The manufacturer of dasabuvir; ombitasvir; paritaprevir; ritonavir and ombitasvir; paritaprevir; ritonavir recommends caution and clinical monitoring if administered concurrently with furosemide.

Use of these drugs in combination has resulted in elevated furosemide maximum plasma concentrations Cmax. Individualize the dose of furosemide based on the patient's clinical response. The dose should be re-adjusted after completion of the hepatitis C treatment regimen. Moderate The manufacturer of dasabuvir; ombitasvir; paritaprevir; ritonavir recommends caution and clinical monitoring if administered concurrently with furosemide. The dose should be re-adjusted after completion of the 4-drug hepatitis C treatment regimen. Desloratadine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.

Desmopressin: Major Desmopressin, when used in the treatment of nocturia is contraindicated with loop diuretics because of the risk of severe hyponatremia. Discontinuation of the SNRI should be considered in patients who develop symptomatic hyponatremia. Dexchlorpheniramine; Dextromethorphan; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Dexlansoprazole: Moderate Proton pump inhibitors have been associated with hypomagnesemia. Dexmethylphenidate: Moderate Dexmethylphenidate can reduce the hypotensive effect of antihypertensive agents, including loop diuretics. Periodic evaluation of blood pressure is advisable during concurrent use of dexmethylphenidate and antihypertensive agents, particularly during initial coadministration and after dosage increases of dexmethylphenidate.

Dextroamphetamine: Minor Amphetamine and Dextroamphetamine may increase both systolic and diastolic blood pressure and may counteract the activity of some antihypertensive agents, such as loop diuretics. Dextromethorphan; Diphenhydramine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Dextromethorphan; Guaifenesin; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.

Dextromethorphan; Guaifenesin; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Dextromethorphan; Quinidine: Moderate Quinidine can decrease blood pressure and should be used cautiously in patients receiving antihypertensive agents due to the potential for additive hypotension. Diazoxide: Moderate Additive hypotensive effects can occur with the concomitant administration of diazoxide with loop diuretics.

This interaction can be therapeutically advantageous, but dosages must be adjusted accordingly. The manufacturer advises that IV diazoxide should not be administered to patients within 6 hours of receiving other antihypertensive agents. Dichlorphenamide: Moderate Concomitant use of dichlorphenamide and furosemide is not recommended because of an increased risk of furosemide-related adverse effects and risk for hypokalemia. Monitor closely for signs of drug toxicity if coadministration cannot be avoided in some patients furosemide dose adjustment might be necessary. Increased furosemide exposure is possible. Dichlorphenamide inhibits OAT1. Furosemide is an OAT1 substrate.

Dichlorphenamide also increases potassium excretion and can cause hypokalemia and should be used cautiously with other drugs that may cause hypokalemia including furosemide. Measure potassium concentrations at baseline and periodically during dichlorphenamide treatment. If hypokalemia occurs or persists, consider reducing the dose or discontinuing dichlorphenamide therapy. Diclofenac: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Diclofenac; Misoprostol: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.

Dicloxacillin: Minor Furosemide may compete with penicillin for renal tubular secretion, increasing penicillin serum concentrations. Diethylpropion: Major Diethylpropion has vasopressor effects and may limit the benefit of loop diuretics. Although leading drug interaction texts differ in the potential for an interaction between diethylpropion and this group of antihypertensive agents, these effects are likely to be clinically significant and have been described in hypertensive patients on these medications.

Diflunisal: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Digitoxin: Moderate Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting drugs such as loop diuretics, increasing the risk of proarrhythmic effects of cardiac glycosides. Digoxin: Moderate Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting drugs such as loop diuretics, increasing the risk of proarrhythmic effects of cardiac glycosides. Dihydrocodeine; Guaifenesin; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics.

Diphenhydramine; Hydrocodone; Phenylephrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Diphenhydramine; Ibuprofen: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Diphenhydramine; Naproxen: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.

Diphenhydramine; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Docusate Sodium; Senna: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives. Docusate: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives. Dofetilide: Major Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting drugs such as loop diuretics increasing the potential for dofetilide-induced torsade de pointes. Potassium levels should be within the normal range prior and during administration of dofetilide.

Dolasetron: Moderate Caution is advisable during concurrent use of dolasetron and loop diuretics as electrolyte imbalance caused by diuretics may increase the risk of QT prolongation with dolasetron. Doxacurium: Moderate Furosemide-induced hypokalemia can potentiate neuromuscular blockade with nondepolarizing neuromuscular blockers. Droperidol: Moderate Caution is advised when using droperidol in combination with loop diuretics which may lead to electrolyte abnormalities, especially hypokalemia or hypomagnesemia, as such abnormalities may increase the risk for QT prolongation or cardiac arrhythmias.

Dulaglutide: Minor Loop diuretics, such as bumetanide, furosemide, and torsemide, may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Empagliflozin: Moderate When empagliflozin is initiated in patients already receiving loop diuretics, volume depletion can occur. Patients with impaired renal function, low systolic blood pressure, or who are elderly may also be at a greater risk for volume depletion and perhaps symptomatic hypotension. Before initiating empagliflozin in patients with one or more of these characteristics, volume status should be assessed and corrected.

Monitor for signs and symptoms after initiating therapy. Loop diuretics can decrease the hypoglycemic effects of antidiabetic agents by producing an increase in blood glucose concentrations. Patients receiving empagliflozin should be monitored for changes in blood glucose control if such diuretics are added or deleted. Empagliflozin; Linagliptin: Moderate When empagliflozin is initiated in patients already receiving loop diuretics, volume depletion can occur.

Minor Loop diurectics may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Because of this, a potential pharmacodynamic interaction exists between these drugs and all antidiabetic agents, such as linagliptin. Empagliflozin; Metformin: Moderate When empagliflozin is initiated in patients already receiving loop diuretics, volume depletion can occur.

Enalapril, Enalaprilat: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Enalapril; Felodipine: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Enalapril; Hydrochlorothiazide, HCTZ: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Enflurane: Moderate General anesthetics can potentiate the hypotensive effects of antihypertensive agents.

Ephedrine: Major The cardiovascular effects of sympathomimetics, such as ephedrine, may reduce the antihypertensive effects produced by loop diuretics. Blood pressure and heart rates should be monitored closely to confirm that the desired antihypertensive effect is achieved. Epoprostenol: Moderate Epoprostenol can have additive effects when administered with other antihypertensive agents. These effects can be used to therapeutic advantage, but dosage adjustments may be necessary. Eprosartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure. Eprosartan; Hydrochlorothiazide, HCTZ: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.

Ertugliflozin; Metformin: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Ertugliflozin; Sitagliptin: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Escitalopram: Moderate Patients receiving a diuretic during treatment with escitalopram may be at greater risk of developing syndrome of inappropriate antidiuretic hormone secretion SIADH.

Discontinuation of escitalopram should be considered in patients who develop symptomatic hyponatremia. Esomeprazole: Moderate Proton pump inhibitors, such as esomeprazole, have been associated with hypomagnesemia. Esomeprazole; Naproxen: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Moderate Proton pump inhibitors, such as esomeprazole, have been associated with hypomagnesemia. Estradiol Cypionate; Medroxyprogesterone: Minor Estrogens can induce fluid retention and may increase blood pressure in some patients; patients who are receiving antihypertensive agents concurrently with hormone therapy should be monitored for antihypertensive effectiveness.

Estradiol: Minor Estrogens can induce fluid retention and may increase blood pressure in some patients; patients who are receiving antihypertensive agents concurrently with hormone therapy should be monitored for antihypertensive effectiveness. Etodolac: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Etomidate: Moderate General anesthetics can potentiate the hypotensive effects of antihypertensive agents. Exenatide: Minor Loop diuretics, such as bumetanide, furosemide, and torsemide, may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia.

Famotidine; Ibuprofen: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Fenoprofen: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Fentanyl: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when diuretics are administered with fentanyl.

Fexofenadine; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. It is possible that additive reductions in blood pressure may be seen when fish oils are used in a patient already taking antihypertensive agents. Fluoxetine: Moderate Patients receiving a diuretic during treatment with fluoxetine may be at greater risk of developing syndrome of inappropriate antidiuretic hormone secretion SIADH.

Discontinuation of fluoxetine should be considered in patients who develop symptomatic hyponatremia. Fluoxetine; Olanzapine: Moderate Olanzapine may induce orthostatic hypotension and thus enhance the effects of antihypertensive agents. Moderate Patients receiving a diuretic during treatment with fluoxetine may be at greater risk of developing syndrome of inappropriate antidiuretic hormone secretion SIADH. Flurbiprofen: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.

Fluvoxamine: Moderate Patients receiving a diuretic during treatment with fluvoxamine may be at greater risk of developing syndrome of inappropriate antidiuretic hormone secretion SIADH. Discontinuation of fluvoxamine should be considered in patients who develop symptomatic hyponatremia. Foscarnet: Moderate Avoid concurrent use of loop diuretics with foscarnet. Coadministration may impair the renal tubular secretion of foscarnet, thereby increasing the possibility for toxicity.

When use of a diuretic is indicated in patients being treated with foscarnet, consider a thiazide diuretic. Fosinopril: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Fosinopril; Hydrochlorothiazide, HCTZ: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Fospropofol: Moderate General anesthetics can potentiate the hypotensive effects of antihypertensive agents. Gallium Ga 68 Dotatate: Major Avoid use of other diuretics with mannitol, if possible.

Concomitant administration may potentiate the renal toxicity of mannitol. General anesthetics: Moderate General anesthetics can potentiate the hypotensive effects of antihypertensive agents. Gentamicin: Moderate The risk of ototoxicity or nephrotoxicity secondary to aminoglycosides may be increased by the addition of concomitant therapies with similar side effects, including loop diuretics.

Ginseng, Panax ginseng: Major Ginseng may decrease the effectiveness of loop diuretics. One case report described a temporal relationship between the use of ginseng and resistance to furosemide therapy, resulting in edema, hypertension, and hospitalization on 2 separate occasions. Other nutritional products were taken concurrently by the patient were not specified in the report. A mechanism of action or causal relationship has not been definitively established.

Glimepiride: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus. Glimepiride; Pioglitazone: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus. Glimepiride; Rosiglitazone: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Glipizide: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus. Glipizide; Metformin: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia.

Glyburide: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus. Glyburide; Metformin: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Granisetron: Moderate According to the manufacturer, caution is warranted when administering granisetron to patients with preexisting electrolyte abnormalities. Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting drugs such as loop diuretics and thiazide diuretics, increasing the potential for cardiac arrhythmias. Guaifenesin; Hydrocodone: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone.

Guaifenesin; Hydrocodone; Pseudoephedrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Guaifenesin; Phenylephrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Guaifenesin; Pseudoephedrine: Moderate The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by diuretics. Haloperidol: Moderate Caution is advisable during concurrent use of haloperidol and loop diuretics as electrolyte imbalance caused by diuretics may increase the risk of QT prolongation with haloperidol.

Concomitant use may also cause additive hypotension. Halothane: Moderate General anesthetics can potentiate the hypotensive effects of antihypertensive agents. Hawthorn, Crataegus laevigata: Moderate Hawthorn, Crataegus laevigata may lower peripheral vascular resistance. Hawthorn use in combination with antihypertensive agents may lead to additional reductions in blood pressure in some individuals. Patients receiving hawthorn concurrently with antihypertensive medications should receive periodic blood pressure monitoring.

Homatropine; Hydrocodone: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Hydralazine; Hydrochlorothiazide, HCTZ: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss. Hydralazine; Isosorbide Dinitrate, ISDN: Moderate Concomitant use of nitrates with other antihypertensive agents can cause additive hypotensive effects.

Hydrochlorothiazide, HCTZ: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss. Hydrochlorothiazide, HCTZ; Irbesartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure. Hydrochlorothiazide, HCTZ; Lisinopril: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Hydrochlorothiazide, HCTZ; Losartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.

Hydrochlorothiazide, HCTZ; Methyldopa: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss. Hydrochlorothiazide, HCTZ; Metoprolol: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss.

Hydrochlorothiazide, HCTZ; Moexipril: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Hydrochlorothiazide, HCTZ; Olmesartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.

Hydrochlorothiazide, HCTZ; Propranolol: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss. Hydrochlorothiazide, HCTZ; Quinapril: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Hydrochlorothiazide, HCTZ; Spironolactone: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss.

Hydrochlorothiazide, HCTZ; Telmisartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure. Hydrochlorothiazide, HCTZ; Triamterene: Moderate Concomitant use of a thiazide diuretiic, or the related drug metolazone, with a loop diuretic can cause additive electrolyte and fluid loss. Hydrochlorothiazide, HCTZ; Valsartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.

Hydrocodone: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Hydrocodone; Ibuprofen: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Hydrocodone; Phenylephrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Hydrocodone; Potassium Guaiacolsulfonate: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone.

Hydrocodone; Potassium Guaiacolsulfonate; Pseudoephedrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Hydrocodone; Pseudoephedrine: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydrocodone. Hydromorphone: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with hydromorphone. Ibandronate: Moderate When the intravenous formulation of ibandronate is used for the treatment of hypercalcemia of malignancy, combination therapy with loop diuretics should be used with caution in order to avoid hypocalcemia.

Ibuprofen lysine: Moderate Ibuprofen lysine may reduce the effect of diuretics; diuretics can increase the risk of nephrotoxicity of NSAIDs in dehydrated patients. During coadministration of NSAIDs and diuretic therapy, patients should be monitored for changes in the effectiveness of their diuretic therapy and for signs and symptoms of renal impairment. Ibuprofen: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Ibuprofen; Oxycodone: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.

Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with oxycodone. Ibuprofen; Pseudoephedrine: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Iloperidone: Moderate Secondary to alpha-blockade, iloperidone can produce vasodilation that may result in additive effects during concurrent use with antihypertensive agents.

If concurrent use of iloperidone and antihypertensive agents is necessary, patients should be counseled on measures to prevent orthostatic hypotension, such as sitting on the edge of the bed for several minutes prior to standing in the morning and rising slowly from a seated position. Iloprost: Moderate Further reductions in blood pressure may occur when inhaled iloprost is administered to patients receiving other antihypertensive agents. Inamrinone: Moderate Hypokalemia may occur due to excessive diuresis during inamrinone therapy. Fluid and electrolyte changes and renal function should be carefully monitored during inamrinone therapy. Incretin Mimetics: Minor Loop diuretics, such as bumetanide, furosemide, and torsemide, may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia.

Indomethacin: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Inotersen: Moderate Use caution with concomitant use of inotersen and diuretics due to the risk of glomerulonephritis and nephrotoxicity. Insulin Degludec; Liraglutide: Minor Loop diuretics, such as bumetanide, furosemide, and torsemide, may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Insulin Glargine; Lixisenatide: Minor Loop diuretics, such as bumetanide, furosemide, and torsemide, may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia.

Insulins: Minor Monitor patients receiving insulin closely for worsening glycemic control when bumetanide, furosemide, and torsemide are instituted. Bumetanide, furosemide, and torsemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Intravenous Lipid Emulsions: Moderate High doses of fish oil supplements may produce a blood pressure lowering effect. Irbesartan: Moderate Coadministration of furosemide and Angiotensin-converting enzyme inhibitors ACE inhibitors or angiotensin II receptor antagonists may result in severe hypotension and deterioration in renal function, including renal failure.

Isocarboxazid: Moderate Additive hypotensive effects may be seen when monoamine oxidase inhibitors MAOIs are combined with antihypertensives. Careful monitoring of blood pressure is suggested during concurrent therapy of MAOIs with diuretics. Patients should be instructed to rise slowly from a sitting position, and to report syncope or changes in blood pressure or heart rate to their health care provider. Isoflurane: Moderate General anesthetics can potentiate the hypotensive effects of antihypertensive agents.

Isoproterenol: Moderate The pharmacologic effects of isoproterenol may cause an increase in blood pressure. If isoproterenol is used concomitantly with antihypertensives, the blood pressure should be monitored as the administration of isoproterenol can compromise the effectiveness of antihypertensive agents. Isosorbide Dinitrate, ISDN: Moderate Concomitant use of nitrates with other antihypertensive agents can cause additive hypotensive effects.

Isosorbide Mononitrate: Moderate Concomitant use of nitrates with other antihypertensive agents can cause additive hypotensive effects. Kanamycin: Moderate The risk of ototoxicity or nephrotoxicity secondary to aminoglycosides may be increased by the addition of concomitant therapies with similar side effects, including loop diuretics. Ketamine: Moderate General anesthetics can potentiate the hypotensive effects of antihypertensive agents. Ketoprofen: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.

Ketorolac: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy. Lactulose: Moderate Loop diuretics may increase the risk of hypokalemia especially in patients receiving prolonged therapy with laxatives. Lansoprazole: Moderate Proton pump inhibitors have been associated with hypomagnesemia. Lansoprazole; Naproxen: Moderate If a nonsteroidal anti-inflammatory drug NSAID and a diuretic are used concurrently, carefully monitor the patient for signs and symptoms of decreased renal function and diuretic efficacy.

Moderate Proton pump inhibitors have been associated with hypomagnesemia. Leflunomide: Moderate Closely monitor for furosemide-induced side effects such as excessive fluid loss or hypotension when these drugs are used together. In some patients, a dosage reduction of furosemide may be required. Following oral administration, leflunomide is metabolized to an active metabolite, teriflunomide, which is responsible for essentially all of leflunomide's in vivo activity. Teriflunomide is an inhibitor of the renal uptake organic anion transporter OAT3. Use of teriflunomide with furosemide, a substrate of OAT3, may increase furosemide plasma concentrations. Levodopa: Moderate Concomitant use of antihypertensive agents with levodopa can result in additive hypotensive effects.

Levomethadyl: Moderate Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting drugs such as loop diuretics, increasing the risk of proarrhythmic effects of levomethadyl. Levorphanol: Moderate Monitor for decreased diuretic efficacy and additive orthostatic hypotension when loop diuretics are administered with levorphanol. Levothyroxine: Moderate Use high doses more than 80 mg of furosemide and thyroid hormones together with caution. High doses of furosemide may inhibit the binding of thyroid hormones to carrier proteins, resulting in a transient increase in free thyroid hormones followed by an overall decrease in total thyroid hormone concentrations.

Levothyroxine; Liothyronine Porcine : Moderate Use high doses more than 80 mg of furosemide and thyroid hormones together with caution. Levothyroxine; Liothyronine Synthetic : Moderate Use high doses more than 80 mg of furosemide and thyroid hormones together with caution. Linagliptin: Minor Loop diurectics may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Linagliptin; Metformin: Minor Furosemide may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Liothyronine: Moderate Use high doses more than 80 mg of furosemide and thyroid hormones together with caution.

Liraglutide: Minor Loop diuretics, such as bumetanide, furosemide, and torsemide, may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Lisdexamfetamine: Minor Lisdexamfetamine may increase both systolic and diastolic blood pressure and may counteract the activity of some antihypertensive agents, such as loop diuretics.

Lisinopril: Moderate Coadministration of loop diuretics and Angiotensin-converting enzyme inhibitors ACE inhibitors may result in severe hypotension and deterioration in renal function, including renal failure. Lithium: Moderate Loop diuretic-induced sodium loss may increase serum lithium concentrations. Start with lower doses of lithium or reduce dosage and frequently monitoring serum lithium concentrations and signs of lithium toxicity. However, the effect of loop diuretics on lithium clearance relative to thiazide diuretics is generally minor. According to the Beers Criteria, concurrent use of lithium and loop diuretics may result in a clinically important drug interaction in older adults; avoid concurrent use if possible.

If the combination is necessary, monitoring of lithium concentrations is recommended. Lixisenatide: Minor Loop diuretics, such as bumetanide, furosemide, and torsemide, may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Cytomegalovirus Disease. Disseminated Mycobacterium avium Complex Disease.

Toxoplasma gondii Encephalitis. Human Herpesvirus-8 Diseases. Herpes Simplex Virus Disease. Varicella-Zoster Virus Diseases. Hepatitis B Virus Infection. Hepatitis C Virus Infection. Herpes Zoster. Pneumocystis Pneumonia. Penicilliosis marneffei. Search Results 1 - of for All. A 10 total. Amphotericin B. B 2 total. Butoconazole Nitrate. C 12 total. Cabotegravir HIV prevention. D 7 total. E 12 total. Ethambutol Hydrochloride. F 7 total.

Foscarnet Sodium. G 4 total. Gardasil 9. H 3 total. Hepatitis B Vaccine. I 8 total. Isentress HD. J 1 total. K 1 total. L 9 total. M 5 total. Moxifloxacin Hydrochloride. N 2 total. O 2 total. P 13 total. Peginterferon Alfa-2a HIV. Peginterferon Alfa-2b HCV. In cases of fungal ball formation in the lung, S. Peer Review reports. Schizophyllum commune is an environmental basidiomycete that is widely distributed in nature and grows well on rotting wood and other plants [ 1 ]. It belongs to the phylum Basidiomycota, subphylum Agaricomycotina, and order Agaricales, which includes the fungi called mushrooms [ 2 ].

However, unlike dikaryotic isolates, monokaryotic isolates do not show characteristic spicules or clamp connections and cannot be identified using phenotypic methods; thus, genetic sequencing is required for identification [ 5 ]. Schizophyllum commune is rarely involved in human disease, but it is the most common basidiomycete among the filamentous fungi to cause infections in humans [ 1 ]. This fungus causes a wide range of clinical manifestations, from allergic reactions to invasive infections, but it is primarily responsible for infections of the respiratory system.

These localizations are consistent with natural airborne transmission through inhalation of basidiospores released into the atmosphere. The infection may remain localized or spread from the original site to other tissues and organs depending on factors such as the immune status of the host, deviation of the nasal septum, use of corticosteroid therapy, and duration of exposure to the spores [ 8 ]. Fungal balls of the lung are masses of fungal mycelium growing in existing cavities. They are found in patients with underlying lung diseases such as tuberculosis, a history of systemic fungal infections, recurrent bacterial pneumonia, lung abscesses, sarcoidosis, and cavitated squamous cell lung cancer [ 4 , 9 ].

In most cases, species of Aspergillus —most commonly A. Cases of pulmonary fungal ball formation caused by S. We report the first case of lung cancer cavity lesion with a fungal ball formation of S. Sequencing analysis of the ITS was used to identify the microorganism. A year-old Japanese man with diabetes and hypertension was admitted to our hospital with hemosputum, a symptom which he had for about 19 months. The chest scan from 18 months earlier showed that the nodule was associated with cavitation. A bronchoscopy was performed, but the cause of the hemosputum was not found. The patient was referred and then admitted to our hospital for diagnosis because the hemosputum persisted and lung cancer was suspected.

There was no other history of dust or tuberculosis exposure, nor any family history, any pets, or any history of gardening or mountain hiking. On examination, the patient appeared well. His temperature was His physical examination findings were unremarkable. His chest radiographs showed a cavitary lesion in the left middle lung field Fig. In addition to lung cancer, aspergilloma and tuberculosis were considered differential diagnoses.

Serum beta-D-glucan and Aspergillus antibody tests were negative. Bacterial culture of his sputum showed oral commensals and methicillin-resistant Staphylococcus aureus. The culture and smear of three series of sputum for anti-acid bacteria were negative. Computed tomography scan of the thorax. The left upper lobe of the lung has a cavity A , B and internal nodule B ; these are indicated using red arrows. A thoracoscopic left upper lobectomy was performed on the patient, and he was discharged on the second postoperative day. Histopathological examination of the cavitary lesion in the left upper lobe revealed squamous cell carcinoma, and the nodule in the cyst was identified as a fungal ball with numerous filamentous fungi on Hematoxylin and eosin staining Fig.

At 72 h, small white colonies developed Fig. Lactophenol cotton blue mounts of slide cultures on CHROMagar of the isolated fungus showed hyaline hyphae with clamp connections and spicules, but no conidia Fig. The image shows the hyaline hyphae with clamp connections small arrow and spicules large arrow. No conidia are visible. Thus, we identified the isolate as S. The final diagnosis was a fungal ball caused by S. The patient has not experienced recurrence of symptoms in 5 months of follow-up.

We report the first case of lung cancer cavity with a fungal ball formation of S. The fungus is an opportunistic pathogen that can cause a wide range of clinical manifestations, including sinusitis, allergic bronchopulmonary mycosis, eye, ear, and skin infections, abscesses, and fungemia; however, human infections are rarely reported [ 1 ]. According to a previous worldwide study of the 71 cases of S. There have been only three previous reports of fungal ball formation by S. However, it has been noted that infections caused by S.

Identification based solely on macro-microscopic characteristics of cultured colonies is challenging in practice because S. Long incubation times are required for its characteristic macroscopic structures to develop, making cultured colonies impractical for clinical diagnosis [ 1 ]. Since the reference spectral library of matrix-assisted laser desorption ionization-time of flight mass spectrometry MALDI-TOF MS is still incomplete, timely use of molecular techniques should be considered the gold standard for diagnosing S.

The infecting organism in our case was finally identified by analyzing the ITS, and a case of fungal ball formation within the lung cancer cavity caused by S. Most cases of fungal balls are associated with Aspergillus [ 4 ]. Certain imaging features—such as the air crescent sign, meniscus sign, and ball-in-hole sign—are associated with the presence of a fungal ball, which results in a collection of air that is shaped like a crescent and that separates the wall of the cavity from an internal mass [ 13 , 14 , 15 ].

These imaging findings have been reported to be associated with a variety of other diseases, and differential diagnosis can be difficult. Other causes of intracavitary masses surrounded by a crescent of air include other fungi, pulmonary hydatid cyst, Rasmussen aneurysm, pulmonary gangrene, intracavitary clot, textiloma, lung cancer, metastases, and teratoma [ 16 ]. In our case, the possibility of lung cancer, aspergilloma, or tuberculosis was considered preoperatively, but the nodule was finally diagnosed as a fungal ball of S. There are very few reports of fungal ball formation within the lung cancer cavity, and all are due to aspergilloma [ 9 , 17 , 18 ].

The possibility of cell—cell interactions i. In our case, the relationship between lung cancer and S. Therefore, S.

Other nutritional products were taken concurrently Tonalpohualli: The Sacred Almanac Of The Mexica Amphotericin B Case Summary patient were not specified in The Butchers Tale Analysis report. Amphotericin B Case Summary usually developed 10—14 days after Amphotericin B Case Summary. Next: Amphotericin B Case Summary A Skin Disease. This article needs additional citations for Amphotericin B Case Summary. This topic last updated: Aug 12,

Current Viewers: